This company listing is no longer active
Myovant Sciences Past Earnings Performance
Past criteria checks 0/6
Key information
-0.8%
Earnings growth rate
8.5%
EPS growth rate
Biotechs Industry Growth | -14.6% |
Revenue growth rate | 79.8% |
Return on equity | n/a |
Net Margin | -48.5% |
Last Earnings Update | 31 Dec 2022 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Myovant Sciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 22 | 379 | -184 | 317 | -1 |
30 Sep 22 | 333 | -190 | 303 | 0 |
30 Jun 22 | 306 | -166 | 277 | 0 |
31 Mar 22 | 231 | -206 | 259 | 0 |
31 Dec 21 | 198 | -228 | 244 | 72 |
30 Sep 21 | 145 | -238 | 222 | 0 |
30 Jun 21 | 67 | -284 | 194 | 0 |
31 Mar 21 | 59 | -255 | 156 | 0 |
31 Dec 20 | 35 | -239 | 126 | 11 |
30 Sep 20 | 33 | -250 | 96 | -102 |
30 Jun 20 | 33 | -254 | 81 | -51 |
31 Mar 20 | 0 | -289 | 82 | 0 |
31 Dec 19 | 0 | -299 | 62 | 59 |
30 Sep 19 | 0 | -284 | 54 | 219 |
30 Jun 19 | 0 | -279 | 48 | 222 |
31 Mar 19 | 0 | -274 | 42 | 0 |
31 Dec 18 | 0 | -247 | 37 | 204 |
30 Sep 18 | 0 | -218 | 33 | 180 |
30 Jun 18 | 0 | -182 | 29 | 150 |
31 Mar 18 | 0 | -143 | 24 | 117 |
31 Dec 17 | 0 | -117 | 21 | 96 |
30 Sep 17 | 0 | -83 | 17 | 67 |
30 Jun 17 | 0 | -88 | 14 | 47 |
31 Mar 17 | 0 | -83 | 12 | 44 |
Quality Earnings: 71M is currently unprofitable.
Growing Profit Margin: 71M is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 71M is unprofitable, and losses have increased over the past 5 years at a rate of 0.8% per year.
Accelerating Growth: Unable to compare 71M's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 71M is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-15.9%).
Return on Equity
High ROE: 71M's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.